Search

everythinglearnresearchcommunity

for

Search:↓

The conversation discusses the potential benefits and risks of participating in the PP405 hair loss trials, emphasizing that those using Minoxidil or finasteride are less likely to be accepted. Participants are interested in the trial as it offers hope for effective treatment without the side effects associated with current medications.

People discussed their intense hair loss treatments, including the use of dutasteride, RU58841, minoxidil, tretinoin, essential oils, microneedling, and various topical sprays. Some users reported success with these methods in preventing hair loss and stimulating hair growth.

Pelage Pharmaceuticals raised $120M for their hair loss treatment, PP405, showing strong investor confidence despite limited data. There is skepticism about its efficacy and long-term effects compared to treatments like GT20029.

The user has experienced hair loss stabilization with dutasteride and oral minoxidil but is considering adding RU58841 for potential regrowth. Another user advises that it may take up to 36 months for full results with dutasteride and warns of possible side effects with RU58841.

Female considering adding topical anti-androgen, seeks advice on RU58841 or pyrilutamid's binding affinity compared to spironolactone.

The conversation discusses alternatives to finasteride for hair loss, including topical treatments like minoxidil, RU58841, CB-03-01, and dutasteride. Users also mention other options like alfatradiol, topical caffeine, and mesotherapy, while expressing concerns about side effects and the effectiveness of these treatments.

Shiseido RCH-01 and Replicel's upcoming trial data release. Users discuss expected release timelines and clarify quarter dates.

New hair loss treatments like VDPHL01, PP405, Gt20029, and Breezula are anticipated, with VDPHL01 possibly releasing in 2027/28. Current treatments include finasteride, dutasteride, and minoxidil, but new options are eagerly awaited.

The conversation is about seeking information on GT20029 from Kintor Pharmaceutical as a potential hair loss cure and inquiring about experiences with CosmeaRNA.

DLQ01, a prostaglandin F2α analog, shows promise for hair growth by directly stimulating PGE2/PGF receptors without needing conversion, and can be combined with minoxidil and retinoids like tretinoin for enhanced effectiveness. Minoxidil's efficacy may be reduced by COX-1 inhibitors, but using prostaglandin analogs like Latanoprost or Bimatoprost can help maintain its effectiveness.

Hair loss discussion includes treatments Minoxidil, Finasteride, and RU58841. Verteporfin considered for treating donor areas after hair transplants.

The conversation is about accessing and purchasing RU58841 or Pyrilutamide for hair loss treatment, with mentions of alternatives like Breezula. Users discuss price differences in various countries and suggest websites like rudirect.com for purchasing.

The user is experiencing hair shedding after using minoxidil and is considering switching to dutasteride while planning to increase their oral minoxidil dose. They also use nicotine pouches, Vyvanse, and GHK-Cu, and have noticed thicker eyebrows and lashes from oral minoxidil.

The conversation discusses the potential effectiveness and future results of the hair loss treatment pp405, with questions about its impact on different hair loss stages and areas. There is anticipation for phase 3 trial results to provide more data, and hope that pp405 could enhance hair transplant outcomes.

Using dutasteride anally as a hair loss treatment, with humorous and satirical comments on its effects and implications.

The conversation is about someone who has been using finasteride and minoxidil for over three years without satisfactory results for hair thinning. They have started using dutasteride and added RU58841 seven months ago but have not seen improvements yet.

The user experienced noticeable hair growth after 9 months using oral dutasteride, with full results expected in 20-24 months. They prefer oral treatments over topical minoxidil due to convenience.

Finasteride and Dutasteride used in combination with RU58841 and microneedling, as a treatment for hair loss. There was discussion on progress of the treatment and potential other methods to consider.

The conversation is about the lack of improvement in hair loss after using Pyrilutamide for 14 weeks, with the original poster unable to use Finasteride due to depression. Replies suggest that Pyrilutamide, like RU58841, may not work for everyone, and a more potent drug is being developed by Kintor.

PP405 is advancing to Phase 2b trials, showing promise from Phase 2a. It may be available in 3-6 years, with trials using a topical gel.

RU58841 powder from a lab supplier was tested at a free drug testing service. The discussion includes using Minoxidil and finasteride for hair loss treatment.

The user is looking for a place to buy topical adenosine online but finds the Shiseido product on Yesstyle too expensive and inconvenient. No specific treatments were discussed.

User tried various hair loss treatments, now switching to Dut and hair transplant. Experienced side effects and plans to track them.

User experienced hair regrowth after eliminating scalp itch with RU58841. Others discussed itch and hair loss connection, and effectiveness of combining RU58841 with 5AR inhibitors.

PP405 is a promising hair loss treatment that may outperform minoxidil and finasteride by reviving dormant follicles and promoting significant regrowth. Results from ongoing trials are awaited, with a potential market release between 2028-2030.

The conversation discusses combining oral dutasteride with topical finasteride to further reduce scalp DHT levels for hair regrowth. Users debate the effectiveness and safety of this combination, with some suggesting alternatives like topical antiandrogens such as RU58841, fluridil, and alfatradiol.

The conversation discusses the lack of updates on GT20029 for hair loss treatment, with some users noting recent reports indicating ongoing data collection. There are mentions of other treatments like Pyrilutamide and Minoxidil.

Winlevi (clascoterone 1%) is being discussed as a potential hair loss treatment. Users are considering its use despite concerns about its delivery method.

RU58841 is discussed for hair loss treatment, with questions about its legitimacy from RUdirect. Minoxidil and finasteride are also mentioned as treatments.

RU58841 5% is theoretically equivalent to 2mg of dutasteride for hair loss treatment, with RU58841 offering higher potential but more variability due to absorption issues. Users discuss the effectiveness of RU58841 and dutasteride, with some preferring dutasteride for consistent results and others finding success with RU58841.